ArticleCureus2019
Refractory Sweet Syndrome Treated with Anakinra.
Article in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Molecular Characteristics of Sweet Syndrome: A Systematic Review.Experimental dermatology · 2024Pooled it
- Atraumatic Splenic Rupture as the Initial Manifestation of Splenic Marginal Zone Lymphoma: A Case Report.Cureus · 2026Article
- Palliative oncodermatology: Management of malignancy-related cutaneous symptoms in the palliative care setting.Journal of the American Academy of Dermatology · 2025Review
- Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome.The Journal of clinical investigation · 2023Article
- New Practical Aspects of Sweet Syndrome.American journal of clinical dermatology · 2022Review
- Neutrophilic Dermatoses: a Clinical Update.Current dermatology reports · 2022Review
- Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy.Frontiers in medicine · 2020Article
- Off-label use of anti-IL-1 drugs in rheumatic diseases.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sweet syndrome, otherwise known as acute febrile neutrophilic dermatosis, is an uncommon disorder characterized by the abrupt onset of painful cutaneous lesions, often with fever and leukocytosis, in patients with underlying infection, malignancy, pregnancy, or drug exposure. We present a case of a young female with long-standing Sweet syndrome refractory to standard treatments and several immunomodulators whose symptoms were ultimately controlled with anakinra.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.